Why Is Fiasp So Hard to Find? [Explained for 2026]

If you've been sent home from the pharmacy empty-handed — or spent an afternoon calling around trying to find Fiasp — you're not imagining things. Fiasp, the ultra-rapid-acting insulin made by Novo Nordisk, has been genuinely difficult to find at many pharmacies since 2024. In 2026, the situation is improving, but it's not fully resolved.

Here's a plain-English breakdown of exactly what's going on, which Fiasp formulations are affected, and what you can do right now to keep your diabetes management on track.

What Is Fiasp and Why Do People Need It?

Fiasp is a brand-name formulation of insulin aspart made by Novo Nordisk. What sets it apart from standard insulin aspart (NovoLog) is speed. Fiasp contains niacinamide (vitamin B3) and L-arginine, which accelerate absorption after injection. Clinical data show Fiasp appears in the bloodstream in approximately 2.5 minutes — compared to about 5.2 minutes for regular NovoLog.

This ultra-fast onset is critically important for people with type 1 diabetes who need tight post-meal blood sugar control, as well as for insulin pump (CSII) users who benefit from the more physiological mealtime response. Unlike standard NovoLog — which should be given 5–10 minutes before eating — Fiasp can be dosed at the start of a meal or within 20 minutes after starting to eat. That flexibility is meaningful for daily life.

Is Fiasp Actually in a Shortage in 2026?

Yes — but the shortage is specific to certain formulations. As of January 2026, the American Society of Health-System Pharmacists (ASHP) continues to list insulin aspart (including Fiasp) as an active drug shortage. The Fiasp FlexTouch prefilled pen has been the most affected product, with supply disruptions beginning in April 2024.

The key point: the Fiasp insulin formulation itself is not the problem. Novo Nordisk has confirmed that the manufacturing difficulty is with the FlexTouch pen delivery device, not with the drug itself. Other Fiasp delivery formats — Penfill cartridges and 10 mL vials — have been more consistently available.

Which Fiasp Formulations Are Affected?

Here's a breakdown of Fiasp formulations as of early 2026:

• Fiasp FlexTouch pen (3 mL, 5-pack): In shortage since April 2024. Some regional improvements reported in 2025–2026, but still intermittently unavailable at many pharmacies.
• Fiasp PenFill cartridge (3 mL): Generally available and can support increased demand.
• Fiasp 10 mL vial: Still available in the US with some regional shortages; used with a standard syringe or reusable pen device.
• Fiasp PumpCart cartridge (1.6 mL): Used with select insulin pumps; availability varies by region.

Why Is the Fiasp FlexTouch Pen in Short Supply?

Several factors have converged to create the current Fiasp availability challenges:

1. Pen manufacturing capacity constraints: Novo Nordisk attributed the FlexTouch pen shortage to manufacturing capacity issues for the pen delivery system specifically — not with insulin production itself.
2. Discontinuation of unbranded insulin aspart: Novo Nordisk discontinued its unbranded (generic-like) insulin aspart effective December 31, 2025. Patients who used that cheaper option now need to switch to brand Fiasp, brand NovoLog, or a biosimilar, increasing demand for remaining stock.
3. Growing diabetes population: Over 38 million Americans have diabetes, and demand for rapid-acting insulin continues to increase year over year.
4. Complex biologic manufacturing: Insulin is a biologic product made through complex processes involving living cells. Unlike small-molecule pills, insulin production can't be ramped up quickly when demand spikes.
5. Pharmacy inventory behavior: Large chain pharmacies often order based on projected demand. During uncertain supply periods, they may reduce inventory, leading to more frequent out-of-stock events at the shelf level.

How Does the Medicare Price Negotiation Affect Fiasp Availability?

Fiasp was selected in 2024 as one of the first 10 drugs for Medicare price negotiation under the Inflation Reduction Act. Negotiated prices became effective in 2026. This is generally good news for affordability, but the transition period — as pharmacies and insurance plans update their pricing systems — has created some confusion and intermittent access issues for Medicare patients.

What Are Biosimilar Alternatives to Fiasp?

Two insulin aspart biosimilars received FDA approval in 2025:

• Merilog (insulin aspart-szjj) by Sanofi — FDA approved February 2025
• Kirsty (insulin aspart-xjhz) by Biocon/Viatris — FDA approved July 2025; designated as interchangeable, meaning a pharmacist can substitute it without calling your doctor

These biosimilars share the same active ingredient as Fiasp but do not contain niacinamide — meaning they behave more like standard NovoLog in terms of onset timing. If you specifically need the ultra-rapid profile of Fiasp (e.g., for post-meal dosing flexibility), discuss the differences with your prescriber before switching.

What Should You Do If Your Pharmacy Is Out of Fiasp?

Here are practical steps you can take right now:

1. Use medfinder: medfinder calls pharmacies near you to check which ones can fill your Fiasp prescription — so you don't have to spend hours on hold.
2. Ask about a different Fiasp format: If FlexTouch pens are out, ask your pharmacist or prescriber about Fiasp PenFill cartridges or vials. The same insulin, different delivery method.
3. Try independent pharmacies: Independent and specialty pharmacies often maintain different inventory levels than large chain stores and may have Fiasp in stock when chains are out.
4. Try mail-order pharmacies: Express Scripts, OptumRx, and CVS Caremark may have larger centralized supplies.
5. Contact NovoCare: Call Novo Nordisk's support line at 1-866-310-7549 for help finding stock and accessing savings programs.
6. Ask your doctor about alternatives: NovoLog, Humalog, Lyumjev, and biosimilars may be covered options. See our guide to Fiasp alternatives for a full comparison.

Will the Fiasp Shortage Get Better?

The outlook for 2026 is cautiously optimistic. Novo Nordisk completed its product discontinuations at the end of 2025, which removes some of the demand uncertainty. Biosimilars like Kirsty and Merilog are entering the market throughout 2026, which should ease pressure on brand Fiasp. Most experts expect supply to stabilize as biosimilar production scales up — but intermittent shortages may continue through mid-2026 at some pharmacies.

The bottom line: Fiasp is not gone. It is available — you may just need to look in the right places or consider an alternative delivery format. Keep your prescription current, refill as early as your insurance allows, and use medfinder to take the phone-tag work out of the equation.

Related Resources

How to Find Fiasp in Stock Near You (Tools + Tips) — practical strategies for locating your insulin.

Fiasp Shortage Update: What Patients Need to Know in 2026 — the latest on the shortage timeline and what's changed.